Document Classification

Section Type: METHODS

Text: Before skin closure, patients received the following treatments : group I (n = 20) patients received normal saline 20 mL wound infiltration and intravenous lornoxicam (Xefo, Nycomed Pharma AS, Roskilde, Denmark) 2 mL (8 mg) ; group II (n = 20) patients received 0. 25 % levobupivacaine (Chirocaine, Abbott Scandinavia AB, Solna, Sweden) 10mL with normal saline 10 mL wound infiltration and intravenous normal saline 2 mL ; group III (n = 20) patients received 0. 25 % levobupivacaine 10 mL with normal saline 10 mL wound infiltration and intravenous lornoxicam 2 mL (8 mg).